Clinical Trials Browser

Urinary Bladder Neoplasms, Bone Neoplasms, Brain Neoplasms, Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Glioblastoma, Hodgkin Disease, Kidney Neoplasms, Leukemia, Lung Neoplasms, Lymphoma, Lymphoma, Non-Hodgkin, Melanoma, Multiple Myeloma, Myelodysplastic Syndromes, Neoplasms, Ovarian Neoplasms, Prostatic Neoplasms, Sarcoma, Osteosarcoma, Skin Neoplasms, Testicular Neoplasms, Thyroid Neoplasms, Leukemia, Myeloid, Acute, Hematologic Neoplasms, Small Cell Lung Carcinoma

NCT02921061 2020-03-17

Decitabine With GCLAM for Adults With Newly Diagnosed, Relapsed, or Refractory AML or High-Risk MDS

Phase 1/2 Completed

28 enrolled 13 charts

Other hematologic neoplasm

Leukemia, Biphenotypic, Acute, Leukemia, Myeloid, Acute

NCT02129101 2019-10-30

Azacitidine and Sonidegib or Decitabine in Treating Patients With Myeloid Malignancies

Phase 1 Completed

63 enrolled

MyeloidOther hematologic neoplasm

Myelodysplastic Syndromes, Polycythemia Vera, Thrombocythemia, Essential, Leukemia, Myeloid, Acute, Leukemia, Myelomonocytic, Chronic, Myelodysplastic-Myeloproliferative Diseases, Primary Myelofibrosis

NCT00416598 2019-02-19

Decitabine as Maintenance Therapy After Standard Therapy in Treating Patients With Previously Untreated Acute Myeloid Leukemia

Phase 2 Completed

546 enrolled 5 charts

Other hematologic neoplasm

Leukemia, Myeloid, Acute, Leukemia, Myelomonocytic, Acute

NCT01729845 2019-02-07

Decitabine Followed by Mitoxantrone Hydrochloride, Etoposide, and Cytarabine in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndromes

Phase 1/2 Completed

52 enrolled 9 charts

Other hematologic neoplasm

Leukemia, Myeloid, Acute

NCT01804101 2018-05-25

Liposomal Cytarabine-Daunorubicin CPX-351 in Treating Patients With Untreated Myelodysplastic Syndrome or Acute Myeloid Leukemia

Phase NA Completed

48 enrolled 9 charts

MyeloidOther hematologic neoplasm

Myelodysplastic Syndromes, Leukemia, Biphenotypic, Acute, Leukemia, Myeloid, Acute

NCT01130506 2017-08-02

Decitabine, Vorinostat, and Cytarabine in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome

Phase 1 Completed

17 enrolled

Other hematologic neoplasm

Leukemia, Myeloid, Acute

NCT00044733 2006-05-18

Study Evaluating Gemtuzumab Ozogamicin in Acute Myelogenous Leukemia After Stem Cell Transplant

Phase 2 Completed

38 enrolled

Other hematologic neoplasm

Leukemia, Leukemia, Myeloid, Acute

Clinical Trials

Pevonedistat and Decitabine in Treating Patients With High Risk Acute Myeloid Leukemia

Geriatric Assessment & Genetic Profiling to Personalize Therapy in Older Adults With Acute Myeloid Leukemia

CPX-351 in Treating Patients With Newly Diagnosed, High-Risk Acute Myeloid Leukemia

DEC-205/NY-ESO-1 Fusion Protein CDX-1401, Poly ICLC, Decitabine, and Nivolumab in Treating Patients With Myelodysplastic Syndrome or Acute Myeloid Leukemia

Liposomal Cytarabine, Daunorubicin, and Gemtuzumab Ozogamicin for the Treatment of Relapsed Refractory Pediatric Patients With Acute Myeloid Leukemia

CHA

Ruxolitinib Phosphate and Decitabine in Treating Patients With Relapsed or Refractory or Post Myeloproliferative Acute Myeloid Leukemia

STAT Inhibitor OPB-111077, Decitabine and Venetoclax in Treating Patients With Acute Myeloid Leukemia That Is Refractory, Relapsed or Newly Diagnosed and Ineligible for Intensive Chemotherapy

IFN-γ to Treat Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS) That Has Relapsed After Allogeneic Hematopoietic Stem Cell Transplantation

Testing Nivolumab in Combination With Decitabine and Venetoclax in Patients With Newly Diagnosed TP53 Gene Mutated Acute Myeloid Leukemia

Azacitidine With or Without Nivolumab or Midostaurin, or Decitabine and Cytarabine Alone in Treating Older Patients With Newly Diagnosed Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome

Efficacy of 5-Aza for Post-Remission Therapy of Acute Myeloid Leukemia (AML) in Elderly Patients

Salsalate, Venetoclax, and Decitabine or Azacitidine for the Treatment of Acute Myeloid Leukemia or Advanced Myelodysplasia/Myeloproliferative Disease

Decitabine With or Without Bortezomib in Treating Older Patients With Acute Myeloid Leukemia

DEC-205/NY-ESO-1 Fusion Protein CDX-1401and Decitabine in Treating Patients With Myelodysplastic Syndrome or Acute Myeloid Leukemia

Bioequivalence & Food Effect Study in Patients With Solid Tumor or Hematologic Malignancies

Decitabine With GCLAM for Adults With Newly Diagnosed, Relapsed, or Refractory AML or High-Risk MDS

Azacitidine and Sonidegib or Decitabine in Treating Patients With Myeloid Malignancies

Decitabine as Maintenance Therapy After Standard Therapy in Treating Patients With Previously Untreated Acute Myeloid Leukemia

Decitabine Followed by Mitoxantrone Hydrochloride, Etoposide, and Cytarabine in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndromes

Liposomal Cytarabine-Daunorubicin CPX-351 in Treating Patients With Untreated Myelodysplastic Syndrome or Acute Myeloid Leukemia

Decitabine, Vorinostat, and Cytarabine in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome

Study Evaluating Gemtuzumab Ozogamicin in Acute Myelogenous Leukemia After Stem Cell Transplant